Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 1/20 | 0.60 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.57 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.57 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.54 |
| ▸ | PPARA | Q07869 | 6/20 | 0.52 |
| ▸ | PPARG | P37231 | 5/20 | 0.52 |
| ▸ | CTSS | P25774 | 9/20 | 0.52 |
| ▸ | CTSK | P43235 | 8/20 | 0.52 |
| ▸ | CTSB | P07858 | 4/20 | 0.52 |
| ▸ | PPARD | Q03181 | 2/20 | 0.50 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.50 |
| ▸ | ITGAV | P06756 | 1/20 | 0.50 |
| ▸ | ITGB5 | P18084 | 1/20 | 0.50 |
| ▸ | CTSL | P07711 | 1/20 | 0.50 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.49 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17933020 | 1.00 | ACE (0.60) | ACEITGB3ITGA2BPTPN1PPARA | |
| SCHEMBL13286814 | 0.90 | ACE (0.58) | ACEITGB3ITGA2BPTPN1PPARA | |
| SCHEMBL15565481 | 0.90 | ACE (0.58) | ACEITGB3ITGA2BPTPN1PPARA | |
| SCHEMBL18553988 | 0.89 | ACE (0.57) | ACEITGB3ITGA2BPTPN1PPARA | |
| SCHEMBL17580391 | 0.89 | ACE (0.57) | ACEITGB3ITGA2BPTPN1PPARA | |
| SCHEMBL15335432 | 0.89 | ACE (0.57) | ACEITGB3ITGA2BPTPN1PPARA | |
| SCHEMBL17933019 | 0.88 | KLK5 (0.55) | ACEITGB3ITGA2BPTPN1PPARA | |
| SCHEMBL10099995 | 0.88 | KLK5 (0.55) | ACEITGB3ITGA2BPTPN1PPARA | |
| SCHEMBL24489507 | 0.88 | ACE (0.56) | ACEITGB3ITGA2BPTPN1PPARA | |
| SCHEMBL10042360 | 0.88 | ITGA4 (0.56) | ACEITGB3ITGA2BPTPN1PPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8722923-B2 | Conjugates for treating neurodegenerative diseases and disorders | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2014-05-13 | — | — | US | disclosed |
| US-20120277310-A1 | NOVEL CONJUGATES FOR TREATING NEURODEGENERATIVE DISEASES AND DISORDERS | BAR-ILAN UNIVERSITY (IL) | 2012-11-01 | — | — | US | disclosed |
| US-8207369-B2 | Conjugates for treating neurodegenerative diseases and disorders | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2012-06-26 | — | — | US | disclosed |
| US-20110034553-A1 | NOVEL CONJUGATES FOR TREATING NEURODEGENERATIVE DISEASES AND DISORDERS | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2011-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120277310-A1 | NOVEL CONJUGATES FOR TREATING NEURODEGENERATIVE DISEASES AND DISORDERS | SLC18A2, GABRB2, SLC6A13 | ACE 2889/4885ITGB3 3514/4885ITGA2B 2364/4885 |
| US-20110034553-A1 | NOVEL CONJUGATES FOR TREATING NEURODEGENERATIVE DISEASES AND DISORDERS | SLC18A2, SNCA, SLC6A13 | ACE 2927/4885ITGB3 3970/4885ITGA2B 2825/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.